IAVI utilizes its expertise and technologies to address unmet global health needs and develop vaccines and antibody products that are accessible to everyone around the world. IAVI is able to do this with the support of various foundations, governmental and non-governmental organizations.
In partnership with Clinical Research Centers in Eastern and Southern Africa, IAVI conducts translational research programs to advance the development of HIV vaccines. This research leads to the accumulation of clinical and laboratory data derived from clinical and epidemiology studies, and the collection and analysis of human donor samples.
To respond to high demand for study data and associated samples a digital repository was developed to support ongoing and future research in HIV vaccine development.
IAVI DataSpace is the portal to access this research and development data. The aim of IAVI DataSpace is to facilitate pioneering, data-driven HIV prevention research using a comprehensive relational database. This project is part of the Accelerating the Development of Vaccines and New Technologies to Combat the AIDS Epidemic (ADVANCE) program supported by the U.S. Agency for International Development (USAID). ADVANCE aligns the latest scientific, technological and collaborative innovations to expedite the translation of scientific advancements into life-saving vaccines and other new prevention products.
Currently the IAVI DataSpace provides access to data from the IAVI Protocol C, which has led to an unprecedented insight into early events of HIV transmission and disease progression.
VISTA meeting in Nairobi, Kenya (September/October 2019)
VISTA (Vaccine Immunology Science and Technology for Africa) partners and postdoctoral fellows will be meeting in Nairobi, Kenya between 30 September and 2 October 2019. VISTA consortia brings together clinical research centres from five African countries with the focus on developing vaccine candidates and assessing the immune responses they induce. The VISTA members will be discussing...
Check out a recent publication on KIRs in HIV that was supported by Protocol C samples
Researchers studied a well-characterized cohort of HIV-1 seroconverters from sub-Saharan Africa who were identified when seronegative and followed under Protocol C of the International AIDS Vaccine Initiative (IAVI). iKIR genes enhance the protective effect of HLA-B*57 on early set-point viral load and time to low CD4 count. The full paper is available in November 2018...
IAVI DataSpace website to be launched at HIVR4P 2018 in Madrid
IAVI will present the IAVI DataSpace at the 2018 HIVR4P annual event in Madrid. The IAVI DataSpace is a portal to gain entry to IAVI’s open-access data warehouse that builds on years of epidemiological, clinical, and immunological data generated by IAVI in partnership with Clinical Research Centers in Eastern and Southern Africa. This is an...
IAVI recognized early on that to develop effective HIV vaccines for use throughout the world, it is essential to build partnerships and bolster capacity to conduct vaccine trials at the highest technical and ethical standards in developing countries, where the need for a vaccine is the greatest.
Today, a network of independent but interconnected research centers in five sub-Saharan African countries (Kenya, Rwanda, South Africa, Uganda and Zambia), as well as India, the UK and USA, play a central role in IAVI’s vaccine development program, testing HIV vaccine candidates and conducting epidemiological studies to inform the design of candidates and provide baseline information for future efficacy trials.
This partnership-based approach emphasizes building capacity by training local researchers and developing the infrastructure required for such research. Investigators within this network are linked to scientific consortia—such as the Center for HIV/AIDS Vaccine Immunology and the Neutralizing Antibody Consortium—and collaborate closely with IAVI researchers.
This program is made possible by the support of the American People through the United States Agency for International Development (USAID) and the US President’s Emergency Plan for AIDS Relief (PEPFAR). The content of this website is the sole responsibility of IAVI and does not necessarily reflect the views of USAID, PEPFAR, or the United States Government.